A randomised phase III study on capecitabine, oxaliplatin and bevacizumab with or without cetuximab in first-line advanced colorectal cancer, the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). An interim analysis of toxicity. [electronic resource]
Producer: 20080416Description: 734-8 p. digitalISSN:- 1569-8041
- Adult
- Aged
- Aged, 80 and over
- Antibodies, Monoclonal -- administration & dosage
- Antibodies, Monoclonal, Humanized
- Antineoplastic Combined Chemotherapy Protocols -- adverse effects
- Bevacizumab
- Capecitabine
- Carcinoma -- drug therapy
- Cetuximab
- Colorectal Neoplasms -- drug therapy
- Deoxycytidine -- administration & dosage
- Disease-Free Survival
- Drug Eruptions -- etiology
- Female
- Fluorouracil -- administration & dosage
- Humans
- Incidence
- Male
- Middle Aged
- Netherlands
- Organoplatinum Compounds -- administration & dosage
- Oxaliplatin
- Severity of Illness Index
- Survival Analysis
- Treatment Outcome
No physical items for this record
Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.